| Item type |
学術雑誌論文 / Journal Article_02(1) |
| 公開日 |
2012-05-17 |
| タイトル |
|
|
タイトル |
Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| 著者 |
河野, 透
Mamiya, Noriaki
Chisato, Naoyuki
Ebisawa, Yosiaki
Yamazaki, Hirotaka
Watari, Jiro
Yamamoto, Yasuhiro
Suzuki, Shigetaka
Asama, Toshiyuki
Kamiya, Kazunori
|
| 書誌情報 |
Evidence-based Complementary and Alternative Medicine
巻 2011,
p. 418481-1-418481-8,
発行日 2011-01-01
|
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
1741-427X |
| DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1093/ecam/nep200 |
| リンクURL |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Copyright © 2011 Toru Kono et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | Copyright © 2011 Toru Kono et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Peripheral neurotoxicity is the major limiting factor for oxaliplatin therapy. Goshajinkigan (GJG), a traditional Japanese herbal medicine, was recently shown to be effective in protecting against the neurotoxicity of taxanes in Japan. We retrospectively investigated the effect of GJG on peripheral neurotoxicity associated with oxaliplatin therapy. Ninety patients with metastatic colorectal cancer that received FOLFOX4 or modified FOLFOX6 therapy were assigned to receive one of the following adjuncts: oral GJG at 7.5 g day^<−1> (Group A, n = 11), intravenous supplementation of calcium gluconate and magnesium sulfate (1 g each before and after FOLFOX) (Group B, n = 14), combined GJG and calcium gluconate and magnesium sulfate therapies (Group C, n = 21), or no concomitant therapy (Group D, n = 44). The incidence of peripheral neurotoxicity was investigated when the cumulative dose of oxaliplatin exceeded 500 mgm^<−2>.When the cumulative dose of oxaliplatin exceeded 500 mgm^<−2>, the incidence of neuropathy (all grades) in Groups A-Dwas 50.0%, 100%, 78.9%, and 91.7%, respectively. It was lowest in the group that received GJG alone. Concomitant administration of GJG reduced the neurotoxicity of oxaliplatin in patients that received chemotherapy for colorectal cancer. |
|
言語 |
en |
| 注記 |
|
|
内容記述タイプ |
Other |
|
注記 |
http://creativecommons.org/licenses/by/3.0/ |
| 資源タイプ |
|
|
内容記述タイプ |
Other |
|
資源タイプ |
text |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
| フォーマット |
|
|
内容記述タイプ |
Other |
|
内容記述 |
application/pdf |
| ID(XooNIps) |
|
|
|
19952054 |
| 閲覧数(XooNIps) |
|
| ダウンロード数(XooNIps) |
|
|
|
952 |
4488.pdf (1.2 MB)
